🇺🇸 FDA
Company

Actinium

Actinium Pharmaceuticals

ATNM pharma USA

Quick answer

Actinium is a pharma company (ATNM) headquartered in NEW YORK, NY, USA with 8 tracked pipeline programs.

Pipeline (8)

project

131I-apamistamab

Acute Leukemia

Phase 3 · small_molecule · active

1 trials project

Iomab-B

Acute Myeloid Leukemia

Phase 3 · small_molecule · active

1 trials project

Cytarabine (Phase 1 only)

AML

Phase 2 · small_molecule · completed

1 trials project

Iomab-B

Non Hodgkin Lymphoma

Phase 2 · small_molecule · active

1 trials project

Lintuzumab-Ac225

Acute Myeloid Leukemia

Phase 2 · mab · active

2 trials project

131I-apamistmab

Sickling Disorder Due to Hemoglobin S

Phase 1 · small_molecule · active

1 trials project

ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

Leukemia

Phase 1 · mab · completed

1 trials project

Lintuzumab AC 225

Refractory Multiple Myeloma

Phase 1 · small_molecule · terminated

1 trials

Patents (8)

patent

US 12410249

Low dose antibody-based methods for treating hematologic malignancies

Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12133849

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-

Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12083192

Methods for treatment of patients with myelodysplastic syndromes

Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11981741

Humanized anti-CD45 antibodies

Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11975081

Bifunctional chelators and conjugates

Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11964948

Bifunctional chelators and conjugates

Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11912780

Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-e

Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11844799

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-

Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)